This site is intended for healthcare professionals

Aldeyra Therapeutics, Inc. announced positive top-line symptom, redness, and Schirmer’s test results from the run-in cohort of the Phase III TRANQUILITY clinical trial of reproxalap in patients with dry eye disease.

Read time: 1 mins
Last updated:28th Jun 2021
Published:8th Jan 2021
Condition: Dry Eye Disease
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest